1358. In vitro Activity of Ceftazidime–Avibactam and Comparator Agents Against Pseudomonas aeruginosa Causing Intra-Abdominal, Lower Respiratory, and Urinary Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016

BACKGROUND: The non-β-lactam β-lactamase inhibitor avibactam (AVI) is active against class A, C, and some class D β-lactamases, in combination with ceftazidime (CAZ) has been approved by the FDA and EMA for treatment of intra-abdominal infections (IAI), lower respiratory tract infections (LRTI), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wise, Mark, Kazmierczak, Krystyna, Stone, Gregory G, Sahm, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252817/
http://dx.doi.org/10.1093/ofid/ofy210.1189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252817/
http://dx.doi.org/10.1093/ofid/ofy210.1189

Ejemplares similares